India  

Bangladesh's Beximo signs covid-19 deal with India's Serum Institute, what is it: Watch | Oneindia

Video Credit: Oneindia - Duration: 01:08s - Published
Bangladesh's Beximo signs covid-19 deal with India's Serum Institute, what is it: Watch | Oneindia

Bangladesh's Beximo signs covid-19 deal with India's Serum Institute, what is it: Watch | Oneindia

As the race for a COVID-19 vaccine rages on, Bangladesh's leading pharma company Beximco has announced it will be investing in Adar Poonawalla's Serum India Limited for development of the vaccine.

The deal is designed to ensure that Bangladesh is among the first countries to receive an agreed quantity of this vaccine from Serum India Limited on a priority basis.

The investment will be treated as an advance for the vaccine.


You Might Like


Related videos from verified sources

Covid: Serum Institute begins human trials, 5 volunteers given first shot [Video]

Covid: Serum Institute begins human trials, 5 volunteers given first shot

The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the city-based Serum Institute of India (SII), began at a medical college and hospital here on..

Credit: HT Digital Content     Duration: 02:01Published
Second national sero-survey to be completed in September first week: ICMR [Video]

Second national sero-survey to be completed in September first week: ICMR

Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said,..

Credit: ANI     Duration: 01:49Published
Covid update: Serum Institute clarifies; SOPs for TV shoots; weekend lockdown [Video]

Covid update: Serum Institute clarifies; SOPs for TV shoots; weekend lockdown

From Serum Institute of India clarifying over availability of vaccine shots to the government announcing new SOPs for resuming film and TV shooting, here are the top updates on coronavirus. Serum..

Credit: HT Digital Content     Duration: 02:32Published